| Grant number: | 14/22799-3 |
| Support Opportunities: | Research Grants - Innovative Research in Small Business - PIPE |
| Start date: | April 01, 2016 |
| End date: | December 31, 2016 |
| Field of knowledge: | Interdisciplinary Subjects |
| Principal Investigator: | Andreas Kaasi |
| Grantee: | Andreas Kaasi |
| Company: | EVA Scientific Indústria, Comércio e Serviços Ltda |
| City: | São Paulo |
| Associated researchers: | André Luiz Jardini Munhoz ; Cecilia Amelia de Carvalho Zavaglia ; Paulo Kharmandayan ; Rubens Maciel Filho |
| Associated research grant(s): | 17/16057-2 - Collagen-based medical devices produced in bioreactors, AP.PIPE |
| Associated scholarship(s): | 16/03463-0 - Biofabrication of collagen-based artificial tissues in purpose-built bioreactors for regenerative Medicine and in vitro testing, BP.PIPE |
Abstract
The innovation proposed in this project lies in the development of Tissue Engineering products applied to disease therapy (Regenerative Medicine) and also to the In Vitro Testing Market, where micro-tissues are produced in accordance with a specific assay for the biomedical, cosmetic, pharmaceutical, chemical and related industries. The development of these new products (based on collagen), in addition to being commercialized by themselves as raw material, will also be utilized as starting material for the production of living biological tissues for pre-clinical studies (in vivo and in vitro), minimizing on the use of animals, especially for the cosmetic industry which is growing at 30% per year, now that there is a new legislation in place on the state level (already passed as law by Governor Alckmin in January of this year; INTERTOX, 2014) and the federal level (CÂMARA DOS DEPUTADOS, 2014) which bans the use of animals for these purposes, with fines of up to BRL1,000,000.00 in cases of violation. This type of restriction against the use of live animals in cosmetics development is already in place in Europe since 2004, under the name of "Cosmetics Directive" of the European Union (2014). The passing of this law in the State of São Paulo and by the Brazilian Congress places Brazil in a select group of countries which have the conviction that animal testing procedures may be replaced by alternative means, which currently is formed by the countries of Israel, India, in addition to the European Union. This application opens up for new artificial living tissue models which can attend to the lack of development options in this industrial sector. It will be attempted to combine the best parts and advantages of the natural approach, establishing an In-House production of collagen (and in the future other polymers such as keratin and elastin), with a view of large scale production, with the flexibility of the synthetic approach. Specifically, instead of producing a synthetic scaffold directly with a 3D printer, bioreactors will be printed with mold compartment made by 3D printing technology, where the natural polymers will enter and therein acquire the desired geometric shape. In parallel and/or in series, the events of cell seeding and tissue conditioning. A system capable of integrating the processes of (1) scaffold manufacturing, (2) cell seeding and (3) bioreactor conditioning will be something innovative and unheard of, not yet seen in the area of Tissue Engineering and Regenerative Medicine. This new approach, integrating the various sub-processes of Tissue Engineering in a single system, to be called "bio-artificial tissue factory", will enable, in Phase II, the necessary scalability to transform and positively impact the Health Area of our country. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |